研究プロトコル：ウイルス型別の母体RSVpreFワクチンの有効性
Anna Mensah1, Rebecca Symes1, Chengetai Mpamhanga2
1United Kingdom Health Security Agency, 61 Colindale Ave, London, NW9 5EQ, UK.
Wellcome open research
|January 8, 2026
まとめ
本研究では、呼吸器合胞体ウイルス（RSV）のゲノム変異が新しいRSVpreF母体ワクチンの有効性に影響を与えるかどうかを評価します。結果は、RSVの型や系統が乳児のRSV予防のための世界的なワクチン展開とサーベイランス戦略を導きます。
科学分野:
- ・logy; Immunology; Public Health
背景:
- Respiratory syncytial virus (RSV) causes significant infant illness and death globally.; A new maternal vaccine (RSVpreF) targeting the prefusion F protein shows promise for reducing disease burden.; The impact of RSV genetic diversity on this vaccine's effectiveness is currently unknown.
研究 の 目的:
- To determine if RSV type or lineage influences the effectiveness of maternal RSVpreF vaccination in preventing infant hospitalizations.; To analyze the relationship between RSV genomic variability and vaccine effectiveness.
主な方法:
- Whole genome sequencing of RSV samples from hospitalized infants in England and Scotland during the 2024-2025 winter season.; Calculation of relative vaccine effectiveness (rVE) for RSV-A and RSV-B using case-control logistic regression and a test-negative design.; Comparison of viral lineages between vaccinated and unvaccinated infants.
主要な成果:
- The study aims to identify if current RSV genomic variability impacts relative vaccine effectiveness (rVE).; Results will indicate if RSV type or lineage affects RSVpreF vaccine performance.
結論:
- Confirmation of no impact from viral genomic variability will support global RSVpreF vaccine implementation.; Evidence of decreased effectiveness linked to RSV type or lineage will necessitate enhanced global molecular surveillance for RSV.
